Key Drivers
- Strong Cash Flow
- Rising Debt Load
- Negative Equity
AIAI Summary
BCRX has become a cash-generative ORLADEYO franchise rather than a typical cash-burning biotech, but the investment hinges on whether management uses its strong free cash flow to deleverage and extend the franchise—not pursue dilutive or debt-funded deals that amplify single-product risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Rising Debt Load
- •Negative Equity
BCRX offers strong profitability, cash flow, and liquidity, but its rising debt and deeply negative equity make deleveraging the key investment risk.
Price Behavior
Key Price Behavior Insights:
- •Persistent downtrend
- •Weak rebound
- •Oversold nearing
BCRX remains in a short-term downtrend below its last-month average, with support at $8.10–$8.20 and a sustained move above $9.10 needed to confirm a rebound.
Rebounded from $8.12 to $8.70 before slipping again
Sentiment & News
Key News Insights:
- •Analyst Upside
- •ORLADEYO Growth
- •Institutional Buying
BioCryst's strong analyst upside, expanding ORLADEYO franchise, and rising institutional interest contrast with share-price weakness, potentially creating a buying opportunity.
Positive operational momentum may support a rerating if BioCryst converts ORLADEYO growth into sustained revenue gains
Similar Companies in Healthcare
Other companies in the same sector with AI ratings